Sonia Nagda, the senior fellow of the Cancer Prevention and Treatment Fund testifies at an FDA advisory meeting on a drug that prevents blood clots in patients taking chemotherapy.
The Patient, Consumer, and Public Health Coalition recommends the FDA should ban the use of DBP and DEHP in excipients to reduce exposure of the general population to dangerous phthalates.
Thank you for the privilege of testifying at this important hearing. I am president of the National Research Center for Women & Families, a think tank dedicated to improving the health of adults and children. I am also testifying on behalf of our Cancer Prevention and Treatment Fund. I was trained in epidemiology at Yale Med […]
In this letter to FDA Commissioner, Dr. Margaret Hamburg, NRC and other coalition members advocate for stronger conflict of interest requirements for members of FDA advisory committees to protect patients and consumers against industry biases.
January 5, 2012 Dr. Jeffrey Shuren, Director Center for Devices and Radiological Health Food and Drug Administration Silver Spring, MD 20993 RE: FDA Needs to Provide Breast Implant Patients and Physicians with Unreported Industry Data about Quality of Life, Connective Tissue Symptoms, Rupture Rates per Patient, and Other Complications Dear Dr. Shuren: At the FDA Advisory […]
Dana Casciotti, the public health research director of the Cancer Prevention and Treatment Fund testifies at an FDA advisory meeting on breast implants.